Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination

University of Giessen42 enrolled

Overview

The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.

The SARS-CoV-2 pandemic has had substantial global morbidity and mortality. While COVID-19 is most commonly characterized as a respiratory illness, extrapulmonary manifestations are a prominent part its clinical spectrum. Kidney disease is a common finding in COVID-19, and has also been rarely described after SARS-CoV-2 vaccination. The main objective of this study is to summarize kidney histopathological findings in patients with COVID-19 and post-SARS-COV-2 vaccination, in whom native kidney biopsy was performed and samples were obtained by the Nephropathology Section, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Covid19 Vaccination Reaction

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * being diagnosed with COVID-19 when kidney biopsy was performed * history of recent homologous or heterogenous vaccine regimen comprising either vector-based vaccines or messenger ribonucleic acid-based vaccines Exclusion Criteria: * Patient refuses participation

Locations (1)

University Clinic Giessen and Marburg - Campus Giessen

Giessen, Hesse, Germany

Outcomes

Primary Outcomes

Frequency of histopathologically confirmed glomerular and tubulointerstitial diseases

Time frame: Kidney biopsy obtained during COVID-19 disease and up to 3 months after SARS-CoV-2 vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.